ArticleTranslational andrology and urology2025
Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal cell carcinoma (RCC) is a prevalent disease within the urinary system, characterized by high mortality rates. Its incidence is increasing each year, posing a significant threat to public health. Currently, the causes of RCC are not fully understood, and there are many limitations in treatment options. Recently, traditional Chinese medicine has gained considerable attention in cancer treatment. Fu Zheng Xiao Yu San Jie Decoction (FZXYSJD) is a well-established treatment for RCC, used for many years at The First Affiliated Hospital of Guangzhou University of Chinese Medicine, and is recognized for its efficacy by both physicians and patients. This study aims to employ methods such as network pharmacology and cell experiments to investigate how FZXYSJD works in treating RCC. Additionally, it seeks to identify new targets that may influence the disease's progression. Methods: First, FZXYSJD drug serum was prepared for cell experiments, including the Cell Counting Kit-8 (CCK-8) assay and colony formation assays. Second, Gene Expression Profiling Interactive Analysis (GEPIA) was applied to explore the specific mechanism of FZXYSJD's suppressive effect in RCC. Western blot analyzed the expression level of E2F transcription factor 5 ( Results: FZXYSJD was found to suppress the proliferation of renal clear cell carcinoma cell lines (786O, ACHN) and promote the Conclusions: FZXYSJD affects cell proliferation in RCC through the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.